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Chromosome 22q11.2 deletion syndrome (22qDS) is an inherited autosomal dominant 
disorder.  It is the second most commonly occurring syndrome, Trisomy 21 being the most 
common. It is the most common microdeletion syndrome. 
The clinical range of features with which affected individuals present is very broad and 
includes congenital heart disease (particularly conotruncal malformations), palatal 
abnormalities, characteristic facial features, and learning difficulties. In total, there are more 
than 180 different phenotypic features associated with 22qDS.  
Due to the wide variability of phenotypic features that can arise in 22qDS it is often difficult 
to know when to test for the syndrome. Oskarsdottir’s criteria are widely used in clinical 
recognition for 22qDS. However, in a study done previously at Red Cross War Memorial 
Children’s Hospital, this same criteria was found to only have a positive predictive value of 
14% for 22qDS. This is likely due to the fact that Oskarsdottir’s study was based on a largely 
Caucasian study population. Our population in Southern Africa is largely non-Caucasian. 
Previous studies have confirmed that non-Caucasian population groups with 22qDS have 
different presenting phenotypic features.  
For this reason, in this study we sought to describe the typical phenotypic features with 
which children with 22qDS present in our local population in South Africa. 
A retrospective folder review was done of the phenotypic features of all patients who had 
had a FISH test done on the suspicion on 22qDS. A total of 144 patient folders were 
reviewed (72 patients who were FISH positive for 22qDS and 72 patients who were FISH 
negative and functioned as the control arm of this study). 
A review on the phenotypic features of children with 22qDS revealed the most common 
presentation to be congenital heart disease (44%), failure to thrive (33%), dysmorphic 
features (32%) and cardiac failure (25%). A positive family history was only noted in 13 
patients. Of those patients with a positive family history of 22qDS, only 5% were proven 
FISH positive for 22qDS themselves (less than the 10% described in the literature). Younger 
children presented more frequently with CHD, while older children presented with 
developmental delay and dysmorphic features. In general, developmental delay, palatal 
abnormalities and feeding difficulties were less common in our study population than 
described in the literature.  Our particular patient population presented with the following 
CHD: isolated VSD (46%), tetralogy of Fallot (20.8%), truncus arteriosus (14.5%), 
PS/pulmonary artery stenosis (20.8%) and interrupted aortic arch (6%). Interrupted aortic 
arch was found to be the most sensitive marker for 22qDS in children with cardiac lesions. 
The cardiac lesions with the highest positive predictive value for 22qDS was non-isolated 
VSD (54%). Dysmorphic features with the highest sensitivity for 22qDS included bulbous 
nose (75%), abnormal digits (64%) and posteriorly rotated ears (68%). 
Primary immune deficiency, thymus abnormalities, cleft palate and behavioural issues were 
described less in this study than previously described in the literature.  
In conclusion, it is clear that non-Caucasian populations have some unique phenotypic 
expressions of 22qDS. It is imperative that clinicians maintain a high index of suspicion for 
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Introduction 
Chromosome 22q11.2 deletion syndrome (22qDS) is an inherited autosomal dominant 
disorder and is the most common microdeletion syndrome. It is the second most commonly 
occurring genetic syndrome, Trisomy 21 being the most common. The vast majority of 
probands have a de novo microdeletion of chromosome 22q11.2. However, about 10 - 15% 
of those affected inherit the 22q11.2 deletion from a parent. Offspring of affected 
individuals have a 50% chance of inheriting the deletion. (1-4) 
Due to the broad spectrum of disease presentation in individuals with the 22q11.2 deletion 
syndrome, and because many clinical characteristics are treatable, it is imperative that 
paediatricians have a high index of suspicion. A recent prospective study at Red Cross 
Children’s Hospital (RCWMCH) has shown that it is frequently missed on clinical grounds, 
with potential adverse impacts on patient management and counselling. (62) 
This syndrome was once known by many names e.g. DiGeorge Syndrome, Velocardiofacial 
Syndrome, Shprintzen Syndrome, Conotruncal Anomaly Face Syndrome, Cayler Cardiofacial 
Syndrome, Autosomal Dominant Opitz G/BBB Syndrome, etc. These were previously 
thought to be different disease entities but research confirmed a common underlying 
defect: microdeletion of a segment on the long arm of chromosome 22. This was then 
renamed CATCH 22 Syndrome. The negative connotations associated with the phrase (it 
refers to a problematic situation for which the only solution is denied by a circumstance 
inherent in that same problem) resulted in the syndrome being renamed chromosome 
22q11.2 deletion syndrome. (1, 4-6) 
The clinical range of features with which affected individuals present is very broad and 
includes congenital heart disease (particularly conotruncal malformations), palatal 
abnormalities, characteristic facial features, and learning difficulties. As many as 77% of 
individuals have an immune deficiency regardless of their clinical presentation. Additional 
findings include hypocalcaemia, feeding problems, renal anomalies, hearing loss (both 
conductive and sensorineural), laryngotracheoesophageal anomalies, growth hormone 
deficiency, autoimmune disorders, seizures and skeletal abnormalities. (2) 
The 22qDS is also associated with an increased risk of malignancy, namely hepatoblastoma, 
renal cell carcinoma, Wilm's tumour, and neuroblastoma. (1, 2, 5) 
In total, there are more than 180 different phenotypic features associated with 22qDS. (6, 7) 
The 22qDS is diagnosed by confirmation of the microdeletion with fluorescence in situ 
hybridization (FISH).  A small percentage (<1%) of individuals with clinical features of the 
22q11.2 deletion syndrome have chromosomal rearrangements involving 22q11.2, such as a 
translocation between chromosome 22 and another chromosome. (8, 9) 
The two probes commercially available for 22q11.2 FISH analysis are TUPLE1 and N25. The 
detection rate of FISH analyses using either probe is thought to be equivalent; however, 
FISH using either one of these probes is not sensitive enough to detect small deletions (<40 
kb) within the 22q11.2 region. (8, 9) 
In 2004, a study in Sweden by Oskarsdottir et al attempted to ascertain the most common 
features associated with the 22q11.2 deletion syndrome. The study included a cohort of 100 
children and adolescents. Based on this information, a scoring schedule (see table 1) was 
developed to aid in the decision to perform a FISH test for the 22qDS. This study is a 
sensitive screening tool for the Caucasian population. However, it has been noted to be less 
sensitive in the screening of non-Caucasians for 22qDS. (10) 
TABLE 1: Guidelines for FISH testing for 22qDS (10) 
Two or more of the 8 clinical domains are required to consider the use of genetic testing for possible 
22qDS; a typical cardiac defect found in infancy is sufficient for testing for 22qDS 
CLINICAL DOMAIN INFANTS PRESCHOOL CHILDHOOD TO 
ADOLESCENCE 




























3. Abnormal calcium 
metabolism 
Hypocalcaemia  Hypoparathyroidism  Hypoparathyroidism  
4. Poor feeding Poor feeding Poor feeding Poor feeding 





























8. Dysmorphic features Dysmorphic 
features 
Dysmorphic features Dysmorphic features 
 
The aim of this study is to ascertain the most common phenotypic features noted in our 
population for 22qDS which might suggest the need for FISH testing (or are predictable of a 
positive FISH test). We also calculate the sensitivity and specificity of the most commonly 
occurring phenotypic features as well as the positive and negative predictive values thereof. 
Using this information, we hope that it will lead to the development of a new phenotypic 
algorithm to better identify 22qDS patients in Sub Saharan Africa. An accurate algorithm will 




After Trisomy 21, 22qDS is the second most common genetic syndrome in man. It is also the 
most common microdeletion syndrome. A microdeletion is defined as a very small deletion, 
usually involving only a fraction of a single chromosomal band. Certain syndromes, such as 
22qDS, are due to deletions that encompass portions of several adjacent unrelated genes. 
The overall incidence of 22qDS is approximately 1 in 4000 to 1 in 8000 live births. However, 
this figure might be an underestimate due to the high rate of perinatal deaths secondary to 
severe congenital cardiac defects. (3) A study done in Sweden showed the mean annual 
incidence of 22qDS to be 14 per 100 000 while the prevalence of 22qDS was 23 per 100 000. 
This increased prevalence was likely due to an increased awareness of the syndrome. (1, 10, 
11)A study done in Atlanta found the incidence to be 1 in 6000 to 1 in 6500 in white, black 
and Asian populations. The incidence was 1 in 3800 in the Hispanic population.(12) This was 
however a small study population and data regarding the Latin American population and 
22qDS are scarce. Similarly, in another small study done in Singapore the incidence was 
found to be 1 in 10 000. (1)  
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As cited in McDonald McGinn et al, probable cases of 22qDS have been recorded as early as 
1829, where it was noted that a syndromic looking child had an absent thymus. (5) 
Sedlackova and Lobdell noted the combination of thymic aplasia and congenital 
hypoparathyroidism in 1955 and 1959, respectively. In 1965 DiGeorge described a group of 
infants with congenital absence of the thymus and parathyroid glands, resulting in T cell 
dysfunction. (5, 6) This became known as Di George Syndrome. Shortly thereafter, Kinouchi 
et al described conotruncal anomaly face syndrome (also known as Takao syndrome), which 
consisted of typical dysmorphism, velopharyngeal insufficiency (VPI), CHD and learning 
disabilities. Almost simultaneously, Sprintzen et al described velocardiofacial syndrome 
(VCFS) in children with VPI, CHD and dysmorphic features. (6) These syndromes, with their 
broad range of phenotypic features, became known by many names, e.g. DiGeorge 
Syndrome, Velocardiofacial Syndrome,  Sprintzen Syndrome,  Conotruncal Anomaly Face 
Syndrome , Cayler Cardiofacial Syndrome, Autosomal Dominant Opitz G/BBB Syndrome, 
etc.(5, 6) Further studies suggested a common denominator between all these syndromes - 
microdeletion of a segment on the long arm of chromosome 22. In 1993, the term CATCH 22 
syndrome (an acronym for cardiac features, abnormal facies, thymic hypoplasia, cleft palate, 
hypocalcaemia and 22q deletions) was coined by Wilson et al, but due to the negative 
connotations associated with the phrase the syndrome was renamed chromosome 22q11.2 
deletion syndrome.(1, 6)  
Genetics 
The reason for the phenotypic variation in 22qDS remains unclear. There is uncertain 
genotype-phenotype correlation even in familial cases. (4, 8, 13) 
Most cases of 22qDS occur de novo. However in 7 - 10% of cases it is inherited from one or 
both parents as an autosomal dominant trait.(1, 4) If one or both parents are affected, there 
is a 50% chance that their offspring will inherit the syndrome. The risk of recurrence to two 
unaffected parents with a previously affected child is less than 1%. (1, 5) 
Delio et al suggested a maternal origin of de novo deletions. A study done on 389 confirmed 
22qDS patients showed de novo deletion was of maternal origin in 56% of probands and of 
paternal origin in 44% of probands. This was a statistically significant maternal bias for 
parent of origin of 22qDS.(14) Previous studies, however, did not show this same result 
(though these studies were all smaller in number). 
The characteristic microdeletion found in chromosome 22q11.2 is at least 10 times more 
common than the next frequent human deletion syndrome, Williams syndrome. (5) A total 
of 5 different 22q11.2 critical regions have been identified for 22qDS. 
Linkage analysis has identified a critical region containing at least 25-30 candidate genes 
called the Di George critical region (DGCR). The typically deleted region (TDR) is usually 3Mb 
in size, which encompasses about 30 genes. These typical deletions occur in the majority of 
cases (90%) (3, 8, 15, 16). However, smaller deletions of less than 1.5Mb have also been 
noted in 8% of cases. These typically occur in the centromeric region of the TDR. This 
encompasses approximately 24 genes. (4) A majority of patients appear to be deleted for 
the entire DGCR. (13, 17-19) Notably, the clinical severity of the syndrome has no 
correlation with the size of the deletion. (3, 20, 21) Both large and smaller deletions appear 
to be the result of homologous recombination between non-allelic flanking low copy repeat 
sequences (LCRS) located within the 22q11.2 region. In a group of 300 patients, 86% of the 
deletions were found to span the same 3 Mb region from LCR-A to LCR-D. In the same 
cohort, 7.3% had a smaller approximately 1.5 Mb deletion extending from LCR-A to LCR-B. 
There were also nine deletions with atypical endpoints.(9, 22-25) 
A study investigating the molecular analysis in 142 patients with phenotypic features 
suggestive of 22qDS found that 110 (77%) were carrying the deletion. Of these, 88% carried 
the 3Mb deletion in the typically deleted region. The remaining 12% carried smaller or 
atypical deletions. No significant genotype-phenotype correlation was found between the 
deletion type and the clinical findings. (9, 13) 
10-15% of deletions are atypical and are usually located distally to TDR. (14, 22, 26) 
 Individuals with 22q11 duplications have also been identified but they seem to be fewer 
than anticipated based upon the prevalence of deletions. Nonetheless they share 
phenotypic similarities to patients with 22qDS. (22, 25) 
Less than 1% of individuals with features of 22qDS have chromosomal rearrangements 
between chromosome 22 and another chromosome, as seen in the Philadelphia 
chromosome (translocation of 22q-9q). (1, 23)  
The T box transcription factor 1 (TBX1) gene expression remains of importance in 22qDS. 
TBX1 is expressed in the pharyngeal mesenchyme and endodermal pouch and encodes a T 
box transcription factor, which is essential in the role of early vertebral development, 
amongst other functions. (24, 27) 
Haploinsufficiency for the TBX1 gene results in decreased proliferation of endodermal cells 
in the branchial arches and impaired pharyngeal artery development. Branchial arches are 
the origin of the anterior facial structures, thyroid gland, thymus and parathyroid glands. (6, 
15) TBX1 also drives expression of other downstream targets e.g. FGF8, FGF10 which are 
important in neural crest formation and MYF5, MYOD which regulate development of 
branchiomeric muscle, possibly explaining swallowing abnormalities which arise in 22qDS. 
TBX1 is expressed in the anterior heart field, which becomes cardiomyocytes in the outflow 
tract. (19, 28) 
Furthermore, TBX1 is expressed in developing brain mesoderm and sclerotomes, which may 
account for behavioural, cognitive and psychiatric disturbances, which are common as well 
as skeletal abnormalities. (1, 5, 24, 27) 
However, the TBX1 locus is not always found in deleted region of 22q11.2, suggesting that 
TBX1 haploinsufficiency is not wholly responsible for the full phenotypic picture. (5, 29) 
Other deleted genes also contribute to the phenotype of affected patients: 
Haploinsufficiency for GPIb(beta) may contribute to thrombocytopenia , while COMT 
haploinsufficiency is implicated as a contributing factor to behavioural and psychiatric 
problems and may be related to a slight increased risk of malignancy. CRKL gene has been 
implicated in cardiac anomalies as well as thymic hypoplasia and craniofacial abnormalities. 
(4, 5, 19, 28) 
Atypical deletions and duplications 
In theory, duplications should occur as frequently as deletions.  Duplications and deletions 
arise simultaneously from interchromosomal meiotic exchange in the 22q11.2 region. This 
results in the unequal crossover of low copy repeats. Consequently, a 3Mb deletion occurs 
on one homolog and reciprocal duplication on the other. (30) 
It is likely that patients with duplications are identified less frequently due to the uncommon 
nature of their occurrence. They present with a less severe phenotype and are thus less 
frequently referred for testing. Even when tested, these patients often remain undetected 
as both FISH testing and SNP arrays are less sensitive to duplications than deletions. 
The duplication phenotype, though usually less severe than 22qDS, most commonly 
presents with developmental delay and neuropsychological issues. They can also present 
with CHD, palatal abnormalities and hypocalcaemia. Additional findings include seizures, 
micro or macrocephaly and hearing loss. (5, 25, 30) 






Diagnosis of 22qDS 
Due to the wide variability of phenotypic features that can arise in 22qDS it is often difficult 
to know when to test for the syndrome. In our population it is difficult to diagnose 22qDS as 
patients often present with less recognisable facial features of the syndrome than what is 
described in the literature. This is most likely because the majority of our population is non-
Caucasian. Few studies have been done on the phenotypic features of 22qDS in non-
Caucasian population groups. Thus, it is important to have a high index of suspicion for this 
syndrome.  
The use of the terms Caucasian and non-Caucasian in previous studies are assumed to mean 
White and non-white races. In the traditional biological anthropology sense of the phrase, 
Caucasian race refers to phenotypically similar groups from various regions that share 
similar cranial morphology. These regions include Europe, western and south Asia and North 
Africa. Non-Caucasian races include the Mongoloid, Australoid and Negroid races. 
Obviously, to classify patients based on their biological anthropology in medical research 
would be tedious and cumbersome. When referring to the phenotypic features of 
Caucasians in the context of 22qDS research, what is meant is that the facial phenotypic 
features of the so-called Caucasians are easier to recognise as 22qDS than non-Caucasians. 
The most commonly used method for diagnosing 22qDS is fluorescent-in-situ hybridization 
(FISH). FISH testing is performed using two probes: the first chromosome 22-specific probe 
identifies (‘tags’) chromosome 22 and the second probe then hybridises to a gene known to 
be present in the commonly deleted region on that same chromosome. A (FISH “positive”) 
diagnosis of 22qDS is established if the second probe is absent from a tagged chromosome, 
thereby indicating that the gene target is deleted. (5) 
The probes commercially available for 22qDS FISH analysis are TUPLE1 and N25. The 
detection rate of FISH analysis using either probe is thought to be equivalent; however, 
neither probe is sensitive enough to detect small deletions (<40 kb) within the 22q11.2 
region. (1) 
The main challenges with FISH testing are:  
1. The turnaround time for testing lies between 3 and 14 days, and is labour intensive. 
2. The possibility of a false negative result: not all deletions have the typical endpoints. Thus, 
FISH testing will not detect atypical deletions if the gene target is not deleted despite the 
presence of a deletion (i.e. the targeted gene is not included in the deletion).    
3. The FISH test is not readily available in many middle to low income countries, which often 
causes unnecessary delays in, or lack of, a diagnosis. Also, FISH testing is not always cost 
effective in resource-restricted countries. Lastly, FISH testing is often not done due to lack of 
awareness of attending practitioners that such a test for microdeletions is available in the 
first place. In fact, in previous years in our own referral centre, only patients with truncus 
arteriosus were traditionally tested for 22qDS. This practice was only changed once research 
on 22qDS at RCWMH found it to be incorrectly limited to a single cardiac phenotype. . 
 
Two alternatives to FISH testing are now more readily available, due to cost reductions in 
genetic testing techniques: 
1. A PCR based testing known as the multiple ligation dependent probe amplification 
(MLPA) assay. This detects gene dosage abnormalities by relative quantifications of DNA. 
Other diagnostic tests include array CGH (comparative genomic hybridization) and multiplex 
qualitative real time PCR. These tests are less available and more expensive than FISH 
testing, but have the added advantage of having a rapid turnaround time. (1, 9, 13) 
2. Single nucleotide polymorphism (SNP) arrays are now also available in some centres. 
These tests have the same turnaround time as FISH testing but are very expensive.  
While genetic testing in general has plummeted in price, in low and middle-income 
countries there still exists a lack of testing infrastructure. 
The advantage of these newer tests is that atypical deletions can be readily identified. (5, 
22, 31, 32).  
FISH analysis and SNP arrays can also be performed antenatally on both cultured 
amniocytes and chorionic villi. Thus, affected parents are able to test their offspring for the 
syndrome as early as 10-12 weeks gestation. (1, 17) 
In all offspring diagnosed with 22qDS, it is recommended that both parents be screened 
regardless of any dysmorphism or family history of 22qDS. All siblings of affected individuals 
should also be screened for the syndrome. 
It is also recommended that routine cytogenetic testing be done at the time that the FISH 
test is performed, as  approximately 1% of patients with 22qDS may have chromosomal 
rearrangements involving 22q11.2 i.e. translocation between chromosome 22 and another 
chromosome. (1) 
Specific phenotypic features of 22qDS 
It is frequently difficult to make a firm clinical diagnosis of 22qDS. The 22qDS phenotype is 
extremely variable, even within affected families, and is the most phenotypically diverse 
syndrome known. No phenotypic features are pathognomonic for 22qDS and more than 180 
different phenotypic features are known. Caucasian patients’ facial features appear 
different to those of non-Caucasians; in addition, patients with atypical deletions present 
more subtly than those with typical deletions. (19, 33) 
Aside from the typical facial dysmorphisms, the most common abnormalities are: 
1. Congenital heart disease: 80% of patients with 22qDS present with CHD. 20% of 
patients will be asymptomatic. 
2. Seizures: Seizures occur in 20% of patients with 22qDS. 40 – 70% of seizures are due 
to hypocalcaemia in the neonatal period. However, seizures may also arise as a result of 
other causes such as sepsis, hypoglycaemia and poor feeding. 
3. Mild immune deficiencies arise in patients with 22qDS, associated with absent or 
hypoplastic thymus. 
4. Failure to thrive (FTT) can arise as a result of feeding difficulties or CHD.  FTT occurs 
in 30% of patients with the deletion. 
5. Developmental delay is quite prevalent and occurs in 80% of patients with 22qDS. 
6. Auto-immune disease occurs in 10-20% of patients with 22qDS.  
7. Cleft palate occurs in 10% of patients. Often clefts are not identified as they are 
subtle submucous cleft palates with VPI. 
8. Hearing loss occurs frequently. A large percentage of hearing loss occurs as a result 
of recurrent otitis media. This common infection occurs in 52% of patients with 22qDS. 
Hearing loss occurs in about 31% of cases and is usually conductive in nature. 
9. Learning difficulties are a common occurrence in 22qDS. 25% of patients with the 
deletion have a normal intelligence quotient (IQ). 33% have a borderline IQ and 29% mild 
mental retardation. 
10. Psychiatric manifestations typically present later in life, but may arise in early 
childhood. As many as 25 – 50% of patients develop schizophrenia. There is also an 
increased risk of autism spectrum disease and attention deficit and hyperactivity disorder 
(ADHD), which in particular, is linked to the development of schizophrenia in 30% of 
patients. There is also an increased risk of generalized anxiety disorder, obsessive-
compulsive disorder and mood disorder. (34) 
An early systematic review found that adults with 22qDS have higher rates of palatal 
anomalies, learning disabilities and mental retardation as compared to paediatric patients. 
This may be due to the difficulty in identifying the signs and symptoms earlier in life.(35) 
Treatment of patients with 22qDS should be targeted to suit the individual patient and their 
particular set of phenotypic features, severity of disease and need for treatment. Early 
diagnosis of 22qDS provides ample opportunity to minimise illness and optimise outcomes. 
This includes the screening for, and management of associated conditions. 
McDonald-McGinn et al described the major phenotypic features of 22qDS, as noted in 
Table 3. 
Table 3: The major phenotypic features in 22qDS in cohort of 906 patients at Children’s 
Hospital of Philadelphia (CHOP)(5) 
  Frequency  
Cardiac lesions  77% 
 Teratology of Fallot 20% 
 VSD 21% 
 Interrupted aortic arch 12% 
 Truncus arteriosus 6% 
 Vascular abnormalities 6% 
Immune deficiency  77% 
Palatal issues VPI 42% 
 Submucous cleft palate 16% 
 Overt palate 11% 
 Cleft lip and palate 2% 
Weschler IQ score Average 18% 
 Low average 20% 
 Borderline  32% 
 Mental retardation 30% 
 
In a cohort of 906 patients, McDonald-McGinn described CHD in 74% of patients with 22qDS 
while 69% had varying degrees of palatal abnormalities. 77% of individuals were noted to 
have immune deficiency, irrespective of the clinical presentation. Additional features 
included hypocalcaemia, feeding problems, renal abnormalities, as well as autoimmune 
disorders (AI), seizures and skeletal anomalies. (1) 
 
Oskarsdottir et al in 2005 described the major presenting phenotypic features of 22qDS. 
Patients were divided into two groups: those diagnosed at less than 2 years of age and 
those between the ages of 2 and 20. Majority of patients were diagnosed later in childhood 
(26% of patients were diagnosed in infancy, while 74% were diagnosed in the older age 
group). The 8 major clinical features investigated were congenital heart disease, thymus 
involvement/ recurrent infections/auto immune disease, hypocalcaemia, feeding issues, 
VPI/speech and language delay, developmental/behavioural abnormalities, dysmorphism, 
and other deformities associated with 22qDS. (10) 
As a result of this study new diagnostic considerations were drafted for the testing of 
children suspected of 22QDS (see table 1). (10) However, this was a study done with a 
majority Caucasian population. We attempted using the Oskarsdottir criteria in a study at 
Red Cross War Memorial Children’s Hospital to screen for patients with 22qDS. In our study 
population (which is largely non-Caucasian), the positive predictive value of this criteria was 
only found to be 14%. This emphasized the difficulty in clinical recognition of 22qDS in the 
Southern African context. (62) 
Brunet et al described a study where 4% of 295 children and adolescents tested positive for 
22qDS. All of these patients presented with dysmorphisms and VPI. Gross motor delay, short 
stature and skeletal abnormalities were also frequently noted. (36) 
Digilio et al investigated 165 patients with confirmed 22qDS and found that 100% of 
patients had facial dysmorphisms, 82% presented with CHD, 80% of patients had speech or 
learning difficulties, 73% had neonatal hypocalcaemia and 69% had T cell deficiencies.(37) 
Dysmorphic features include a long face, malar flattening, hypertelorism, hooded eyelids, 
narrow palpebral fissures, prominent nasal root, bulbous nasal tip, hypoplastic alae nasae, 
microglossia, micrognathia, and abnormal helices.(38-40) Interestingly, patients with 
atypical distal deletions seem to differ from those with the “typical” 22qDS phenotype.  
They tend to present with arched eyebrows, deep set eyes, a thin upper lip with a smooth 
philtrum and a small pointed chin. Distal deletions are also associated with postnatal growth 
restriction and short stature. (26) 
Oskarsdottir et al published a study in 2008 describing the typical facial characteristics found 
in 80 patients with 22qDS. They found that at least 50% of patients had malar flatness, 
hooded eyelids, broad nasal bridge with broad or round nasal tip, round ears, thick or 
overfolded helices and low set ears. At least 30% of patients had short palpebral fissures, 
hypertelorism, hypoplastic alae nasae, small round nares, a small mouth and hypoplastic ear 
lobes. The most common feature found overall was the round shape of the ears. Based on 
these findings a guideline was proposed for the screening of 22qDS (Table 4). (39) 
 
 
Table 4: Guideline for screening of 22qDS(39) 
 Feature Score: 0 or 1 
Malar area Malar flatness   
Eye region Fullness of eyelids  
(= Hooded eyelids) 
 
Nose Broad nasal bridge 
Broad/round nasal tip 
 
Ears Round/broad 
Thick/overfolded helix  
Low-set 
 
  Total score = 
 
❖  One point is allocated for each part of the face/head if one or more of the features 
in each area are present. 
❖  A total score of 3 or 4 in combination with clinical features commonly associated 
with the 22q11 deletion syndrome indicates increased likelihood of 22qDS. A lower 
score does not exclude the diagnosis (39) 
 
Veerapandiyan et al described the dysmorphic features of patients with 22qDS in the black 
American population (See Table 5). (38) This study comprised 50 patients and indicated that 
96% of the study population had involvement of at least one system. Most common 
dysmorphic features noted were ear abnormalities, skeletal abnormalities, cardiovascular 
abnormalities and developmental delay. Less commonly, immune deficiency and endocrine 










Table 5: Dysmorphic features of 50 African American patients by Veerapandiyan et al (38) 
Ear abnormalities (including small ears and abnormal 
helices) 
64% 
Skeletal abnormalities (including long fingers, 
camptodactyly, post axial polydactyly, scoliosis, flat feet, 
clubbed feet and clinodactyly) 
64% 
Developmental delay 58% 
Cardiovascular abnormalities (namely tetralogy of Fallot, 
VSD and truncus arteriosus) 
52% 
Nasal abnormalities (e.g. widened nasal bridge) 50% 
Eye abnormalities (including short palpebral fissures, 
hypertelorism, epicanthic folds) 
40% 
Palatal abnormalities (e.g. high palate and submucous cleft 
palate) 
38% 
The nervous system abnormalities (seizures, hypotonia and 
microcephaly) 
38% 
Renal abnormalities 30% 
Micrognathia 16% 
 
The largest study on the Latin American population to date was a Chilean study involving 
208 patients with confirmed 22qDS, investigated for phenotypic features of the deletion 
(see table 6). These findings were then compared to 6 other published studies from Europe, 
Japan and USA that used similar data collection techniques. The frequency of CHD was 
found to be 60%, with TOF being the most commonly occurring cardiac lesion. This was 
lower than described in other studies done previously (except for Oskarsdottir et al, which 
yielded a result of 70% frequency of CHD). The types of CHD described were similar to 
previously published data, namely TOF, VSD, interrupted aortic arch type B, ASD, truncus 
arteriosus and coarctation of the aorta. Palatal abnormalities were found in 79% of patients, 
which was higher than the 56% shown in previously done studies. 
 Feeding difficulties occurred in one third of patients with 22qDS. Hypocalcaemia occurred 
in 35% of cases, mild to moderate mental retardation occurred in 39% of cases, 
developmental delay in 85% of patients and learning difficulties in 92% of cases. 
Hypothyroidism was found in 18% of patients with 22qDS. No cases of juvenile idiopathic 
arthritis were found. Hernias (umbilical, epigastric and inguinal) occurred in 14% of cases, 
skeletal abnormalities in 31 % of cases and primary immunodeficiency in 4% of cases. 
Dysmorphic features were similar in all studies.(41) 
Table 6: Clinical features of Chilean patients with 22qDS (Repetto et al) (41) 
Number of patients 208 
Developmental delay 85% 
Palatal abnormalities 79% 
• VPI 40% 
• Submucus cleft palate 23% 
• Cleft lip and palate 1.4% 
Congenital heart disease 60%  
• Tetralogy of Fallot 20% 
• VSD 12% 
• IAA type B 7% 
• ASD 3% 
• Truncus arteriosus 2.4% 
• Coarctation 2% 
Mental retardation 39% 
Hypocalcaemia  35% 
Skeletal Abnormalities 31% 
Hypothyroidism  18% 
Hernias (umbilical, 
epigastric and inguinal) 
14% 
CNS abnormalities 12% 
Renal abnormalities 11% 
 
 
A study done in India showed that the combination of extracardiac features had 93% 
agreement with presence of 22qDS when found in conjunction with CHD. The combination 
of low set ears, abnormal pinna, bulbous nose and long fingers were present in 91% of 
patients with 22qDS with cardiac lesions. (31) 
Less common clinical features of 22qDS include dysphagia, growth hormone deficiency, 
auto-immune disease, hearing loss and psychiatric illness. (1) 
Not infrequently, structural anomalies occur, including skeletal anomalies, genito-urinary 
tract anomalies, airway anomalies, eye abnormalities, CNS abnormalities and GIT 
anomalies.(1) 
Prevalence of structural heart disease 
Only 20% of patients with 22qDS have a structurally normal heart. The typical cardiac 
defects that occur in 22qDS are conotruncal abnormalities and aortic arch defects. Typical 
examples include tetralogy of Fallot, interrupted aortic arch type B (IAA), VSD, and truncus 
arteriosus. CHD significantly affects the morbidity and mortality of patients with 22qDS. A 
right-sided aortic arch, aberrant subclavian artery, cervical origin of the subclavian artery, 
abnormal pulmonary arteries and major aorto-pulmonary collateral (MAPCA) vessels are 
associated cardiovascular abnormalities in 22qDS. (1, 4, 16, 28, 40, 42, 43)  
Goldmuntz et al described the prevalence of 22qDS in patients with CHD. 251 patients with 
conotruncal CHD were tested for 22qDS. 22qDS was found in 50% of patients with 
interrupted aortic arch, in 34% of patients with truncus arteriosus and in 16% of patients 
with tetralogy of Fallot. No patients with transposition of the great arteries were found to 
carry the deletion. The frequency of 22qDS increased with the presence of vascular 
anomalies, namely anomalies of the pulmonary artery, or the aortic arch and its 
branches.(44) 
A study by Peyvandi et al described the prevalence of 22qDS in CHD in a cohort of 1610 
patients. 13% of patients tested positive for 22qDS. The highest prevalence was found in 
patients with interrupted aortic arch type B (56%) while the prevalence is lowest in DORV 
and TGA (<1% each). Pulmonary atresia, abnormal aortic arch and MAPCA’s occurred more 
commonly in deleted patients. In fact, patients with an abnormal aortic arch anomaly were 
3 times more likely to test positive for 22qDS. Alternatively, DORV and TGA are unlikely to 




Foksteun et al investigated 110 patients with CHD. 17% were confirmed FISH positive for 
22qDS. All of the patients with 22qDS and CHD also had extracardiac features of 22qDS. 
TOF, PA with VSD, truncus arteriosus and interrupted aortic arch were the most commonly 
occurring cardiac lesions in the FISH positive study population. All patients with isolated 
CHD (i.e. isolated cardiac malformation with the absence of any other syndromic features) 
tested negative for 22qDS. This suggests that isolated CHD is not likely to be due to 
22qDS.(45) 
Smaller studies done by Giray et al, and Wozniak et al showed similar results.(21, 46) 
About 14-18% of patients with 22qDS have VSDs. McElhinney et al investigated the 
prevalence of different types of VSDs in 22qDS. 125 patients with perimembranous VSD 
(80%), conoseptal VSD (9%) and posterior malalignment of VSD (11%) were included in the 
study. 22qDS was detected in 10 of patients. Common anatomic abnormalities noted in all 
22qDS positive patients included right sided aortic arch, abnormal branching of the aortic 
arch, a cervical aortic arch and discontinuous pulmonary arteries. Of the 20 patients with 
anatomical abnormalities, 45% tested positive for 22qDS. No correlation was found 
between the type of VSD and 22qDS. However, only certain types of VSD were included in 
the study.(47) 
Botto et al. also noted that most children with CHD and 22qDS also had multiple minor 
features. Conversely, the syndrome was unlikely in children with CHD without these 
features.(48) 
A study done in India showed that of 250 patients with CHD, 21% had conotruncal defects 
associated with a chromosomal abnormality. Of these patients 94% had 22qDS. The types of 
CHD described were as follows: tetralogy of Fallot (TOF), TOF with pulmonary atresia, DORV, 
truncus arteriosus and IAA. The frequency of 22qDS in conotruncal defects was 19%. Also, a 
right-sided aortic arch seems to be associated with increased risk of 22qDS in patients with 
TOF and TOF/pulmonary atresia.(16, 31) Halder et al also described the increased 
probability of 22qDS in patients with conotruncal cardiac defects. This North Indian study 
found 6% of 146 patients with cardiac malformation to have the syndrome.(49) 
A French study rendered similar results: 261 fetuses suspected of having conotruncal 
malformations on antenatal ultrasound were tested for the deletion in utero. 20% of fetuses 
with conotruncal malformations were found to have 22qDS. Of those with 22qDS, TOF was 
found in 14% of cases, pulmonary atresia/VSD was noted in 21% of cases, truncus arteriosus 
in 31% of cases, interrupted aortic arch in 45% of cases and transposition of the great 
arteries in 12% of cases.(50, 51) 
 
 
A Korean multicentre study reviewed 222 patients with 22qDS. 190 patients had CHD. The 
most common cardiac lesions were TOF (63%), isolated VSD (20%), IAA type B (5%), DORV 
(3%), isolated ASD (3%) and TA (1%). Right sided aortic arch was found in 50% of patients, 
while aberrant subclavian artery was found in 30% of patients. Overall, CHD was found in 
85% of patients with 22qDS. This study showed the prevalence of various types of CHD in 
Asia seemed to differ from those found in the western world. DORV, heterotaxy syndrome 
and subarterial VSD prevalence were shown to be higher in Asians than Caucasians. TOF 
with or without PA was more common in the Asian population with 22qDS than the 
Caucasian population with 22qDS while IAA and TA occurred less commonly.(52) 
The mortality of patients with 22qDS is largely attributed to cardiac disease.(5, 43) Thus all 
patients with CHD suspicious of 22qDS must be screened for the syndrome.(3) 
22qDS patients with CHD are also associated with significant morbidity, particularly in the 
area of neurodevelopment, with higher rates of motor and mental delay than other patient 
with CHD.(7) 
Dysmorphic features 
Dysmorphic features are variable and often non-specific. Patients with 22qDS may present 
with ear abnormalities, nasal abnormalities, hypertelorism, asymmetric crying facies, and 
craniosynostosis. The asymmetric crying facies is secondary to hypoplasia of the depressor 
anguli oris muscle and occurs in 20% of patients with 22qDS.Other dysmorphism includes 
polydactyly, syndactyly, clubfoot and overlapping toes. (1, 37, 40) 
Digilio et al. described 100% occurrence of facial dysmorphism in their study population of 
165 patients with proven 22qDS. Neonates were found to have more subtle facial 
dysmorphism compared to older children with 22qDS. Facial dysmorphism ranged from mild 
to severe and included the following: narrow, up slanting palpebral fissures, large bulbous 
nose with hypoplastic nares, microstomia, and small dysmorphic ears.(37) 
Palatal and speech abnormalities 
About 8% of individuals with a cleft palate may have 22qDS, making 22qDS the most 
common genetic syndrome associated with cleft palate. Palatal abnormalities include overt 
or submucosal cleft palate, velopharyngeal incompetence (VPI) and speech delay. As early 
as 1997 McDonald- McGinn suggested that detection of 22qDS in cardiac patients may be a 
risk factor for VPI.(2) 
In a European collaborative study, 496 patients with 22qDS were investigated for palatal 
abnormalities. 14% of patients had an overt cleft palate or a submucous cleft palate. 32% of 
patients had VPI. Zori et al confirmed that 38% of the 16 patients with VPI tested positive for 
22qDS.(54) 
McDonald-McGinn et al showed that 69% of patients with 22qDS had palatal involvement. 
The most common problem was velopharyngeal insufficiency (VPI) occurring in 27% of 
patients.(1) Digilio et al showed a similar result, with 66% of patients with 22qDS having 
palatal abnormalities. The spectrum of palatal involvement was wide with the majority of 
patients presenting with VPI in the absence of a cleft palate.(37)  
CHD combined with cleft palate has a high sensitivity for 22qDS. A study done in Norway 
showed 33% of patients with CHD and cleft palate had 22qDS.(30, 55) 
A study by Sprintzen et al. showed in a sample of 580 known 22qDS patients that included 
overt, submucous and occult submucous cleft palates, that 7% patients had major CHD and 
3% had minor CHD. However, in a study by Friedman et al, no relationship was found 
between CHD and cleft palates in patient population of 316 known 22qDS patients. (16, 55) 
Other oral manifestations of 22qDS include abnormalities in dental enamel, tooth shape or 
number and dental caries.(56) 
Feeding issues 
A third of children present with feeding difficulties requiring some sort of intervention (i.e. 
nasogastric feeding or PEG placement). Feeding issues may arise with or without CHD or 
palatal abnormalities. This is likely due to dysmotility, which occurs in the pharyngo-
oesophageal area. This area is derived from the third and fourth pharyngeal pouches. This 
results in nasopharyngeal reflux, as well as prominence of the cricopharyngeal muscle with 
abnormal cricopharyngeal closure.(1) Feeding difficulties are often overlooked. 
ENT Abnormalities 
Numerous ear abnormalities occur in 22qDS. These include abnormal helices, protruberant 
ears, preauricular pits or tags and narrow external auditory meati. Patients with 22qDS are 
often noted to have a bulbous nose with hypoplastic alar nasae and nasal dimples. Stridor 
can occur secondary to a vascular ring, laryngeal web or laryngomalacia. Chronic otitis 
media and sinusitis are common. 
Hearing loss is a major contributor to speech delay. Both conductive and sensorineural 
hearing loss may occur. Conductive hearing loss is more common and occurs in 45% of 
patients. It is often associated with palatal abnormalities. Sensorineural hearing loss occurs 





Hypocalcaemia is especially common during the neonatal period as well as pre- and post-
cardiac surgery. It is seen in 17-60% of patients with 22qDS. This is most commonly 
secondary to hypoparathyroidism. Most patients do not require prolonged calcium 
supplementation. Hypocalcaemia tends to improve in the first years of life. This is due to 
parathyroid gland hypertrophy. (1, 29, 37, 40) 
Late onset hypocalcaemia has been described quite frequently in the literature, often 
occurring during periods of metabolic stress e.g. puberty, infection or pregnancy.(4, 5) 
During baseline periods, calcium and parathyroid hormone levels remain normal.  
Developmental delay 
The degree of developmental delay is highly variable. It can range from mild learning 
disabilities to mental retardation.(4) 
Mathematical skill, visuo-spatial memory and abstract reasoning are most commonly 
affected. Expressive language and speech skills are also delayed while receptive skills remain 
near normal. The mean age of onset of speech is 30 months. (5, 40, 57)  
Mean IQ is 75 while severe mental retardation is uncommon. 35 – 40% of patients with 
22qDS have mild to moderate mental retardation. Learning disabilities and concentration 
disabilities occur frequently. These are often subtle and may not be detected by the school 
system.(4, 57-59) 
Immune deficiency 
The immune system is affected in 77% of patients with 22qDS. This is the result of thymic 
aplasia or hypoplasia. Commonly, infants with low T cell counts improve over the first year 
of life. Thereafter the T cell count will decline as per usual in unaffected children. Many 
adult patients have T cell counts comparable to unaffected peers. Impaired T-cell 
production occurs in 67% of patients while 19% have impaired T-cell function, 23% have 
humoral defects, and 13% have IgA deficiency.(1, 33, 37, 40) 
Regarding upper respiratory tract infections, 25% to 33% of patients experience recurrent 
ear infections or sinusitis while less than ten percent of patients develop recurrent episodes 
of lower respiratory tract infections.(29) However, these may also be secondary to VPI 
(velopharyngeal insufficiency) and aspiration events. 
Associated abnormalities like CHD, gastro oesophageal reflux, palatal abnormalities and 
aspiration pneumonia also contribute to recurrent infection.(1) 
 
The fetal thymus can also be a useful additional marker of 22qDS. Chaoui et al showed the 
sensitivity for predicting 22qDS in a fetus with signs of CHD and a hypoplastic or absent 
thymus on fetal ultrasound was found to be 90%, while the specificity for prenatal detection 
of 22qDS was 99%. (51) 
Autoimmune disease 
Auto immune (AI) disease is seen in about 10% of patients. The most common autoimmune 
disease in 22qDS are juvenile idiopathic arthritis (JIA) and haemolytic auto immune disease 
like idiopathic thrombocytopenic purpura (ITP).(1, 29, 33) 
JIA occurs in 22qDS at a frequency that is 20 times greater than that of the general 
population. ITP occurs 22 times more frequently in patients with 22qDS than in the general 
population.  Other AI disease includes Grave’s disease, vitiligo, haemolytic anaemia, 
autoimmune neutropaenia, aplastic anaemia and celiac disease.(1) 
Children with JIA also have an increased risk of selective IgA deficiency (2-4% versus 0.25% 
incidence in the general population).(27) 
Allergic disease has also been noted to be increased in 22qDS. 
Eye anomalies 
Refractory errors in 22qDS are more common than in the general population. Astigmatism, 
hypermetropia, posterior embryotoxon and tortuous retinal vessels are frequent eye 
problems.(5) 
Forbes et al investigated 90 patients with 22qDS for eye abnormalities. Almost 50% of 
patients had posterior embryotoxon, 34% tortuous retinal vessels, 20% hooded eyelids 
(upper, lower or both lids affected), 18% strabismus, 4% ptosis, 4% amblyopia (which is 
similar to that observed in the general population) and 1% tilted optic nerves. 
Patients also presented with refractory errors, namely hyperopia. With increasing age the 
prevalence of hyperopia decreased while the prevalence of myopia increased. The majority 
of patients also had mild astigmatism.(1, 60) 
Thus, all children with 22qDS should be evaluated for eye abnormalities and refractory 




Behavioural and psychiatric issues 
Psychiatric disorders arise commonly in 22qDS. These include attention deficit and 
hyperactivity disorder, poor impulse control, bipolar mood disorder, autism spectrum 
disorder, schizophrenia/schizoaffective disorder. The latter occurs in 10-30% of older 
patients.(5, 59) However, not many studies have been done on the prevalence of psychiatric 
disorders in young children. 
Behavioural disorders and psychiatric disease occur in conjunction with developmental 
delay. Autism spectrum disorders occur in approximately 20% of patients with 22qDS. Also, 
anxiety and social withdrawal have been commonly noted.(1) 
Renal and gastrointestinal anomalies 
Renal and gastro intestinal abnormalities have a significant impact on morbidity. 
Renal abnormalities occur in about 30-40% of patients with 22qDS. These include single 
kidney, multicystic dysplastic kidneys, renal calculi, horseshoe kidney, duplex collecting 
system, hydronephrosis, enuresis and renal tubular acidosis. GIT abnormalities include 
constipation, imperforate anus, malrotation, Hirschsprung disease, diaphragmatic hernia 
and umbilical/inguinal hernia.(1, 61) 
Other associations 
Most patients with 22qDS reach normal adult height. However, a study including 95 children 
showed that 41% were below the 5th centile in height for age. All of these children had low 
levels of insulin growth factor (IGF1) and IGFBP3. Three of these children had growth 
hormone deficiency.(1) 
22qDS is associated with Bernard-Soulier syndrome (BSS). BSS is an autosomal recessive 
disorder resulting in thrombocytopaenia and giant platelets. It is caused by a mutation in 
one of 4 genes, of which one (GP1BB) maps to chromosome 22q11.2. BSS will thus arise in 
22qDS patients who have the mutation on their non-deleted chromosome 22. These 
patients are particularly susceptible to bleeding after surgical procedures. (1) 
Malignancies have been reported in 22qDS but it is uncertain if a causal relationship exists 
between 22qDS and certain malignancies. Malignancies specifically mentioned in the 
literature include hepatoblastoma, Wilms tumour, renal cell carcinoma and 
neuroblastoma.(1) 
It is imperative that all patients known with 22qDS should be closely followed up, even as 
adults, to ensure minimum morbidity and mortality. 
 
In 2011, Bassett et al published guidelines on the management of 22qDS.  The guidelines 
were based on two international 22qDS consensus meetings, as well as a systematic review 
of 239 publications on 22qDS. Published guidelines included a list of the multi system 
features, recommendations at diagnosis and considerations for genetic counselling.(13) (see 




Overall objective: To describe the typical phenotypic features with which individuals with 
22qDS present in our local population in South Africa. 
Specific objectives include: 
1. To review all the phenotypic features with which these patients present, including 
immunological and endocrine features. 
2. To perform a classification analysis of these phenotypic features in confirmed cases 
of 22qDS, including calculation of sensitivity and specificity of the most commonly 
occurring features as well as the positive and negative predictive values thereof. 
Ultimately, the goal of this study is to use this information to develop a new phenotypic 




Red Cross War Memorial Children’s Hospital 
B) Methodology: 
A retrospective folder review was done of all patients with a confirmed (FISH positive) 
22qDS. All FISH tests were recorded on a database at the NHS cytology laboratory at Groote 
Schuur Hospital in Cape Town. The database was accessed and all patients who were tested 
for 22qDS were noted. It was from this pool of data that patients were selected to form 
both part of the control group (confirmed FISH negative) and the experimental group 
(confirmed FISH positive). Once this data was extracted from the database, these patients’ 
folders were accessed at Red Cross Hospital and a full retrospective folder review was done.  
The study population presented at various ages between the years 1990 and 2014. 769 
patients were included on the FISH database, of which 120 patients tested FISH positive for 
22qDS. However, not all 120 patient folders were retrievable. A total of 72 FISH positive 
patients’ records were found. Thus, 72 patients with a positive FISH test were compared to 
72 patients with a negative FISH test (the control group), with regards to their phenotypic 
presenting features. Demographic data and family history was noted. All possible 
phenotypic features noted in the folders were recorded.  
These included dysmorphic features, cardiac lesions and any other phenotypic features, 
which may be associated with 22qDS. Using these data, the most common presenting 
features were noted in both FISH positive and FISH negative patients. The sensitivity and 
specificity as well as the positive and negative predictive values of these presenting features 
were then calculated. The most common cardiac lesions were also recorded, and the 
sensitivities, specificities, PPV and NPV were calculated for each cardiac variable. All possible 
dysmorphic features found in patients’ folders were noted. These features were then 
compared in FISH positive and FISH negative patients. The sensitivity, specificity, PPV and 
NPV were calculated for each dysmorphic feature. The dysmorphic features included 
hypertelorism, truncal hypotonia, low set ears, flat nasal bridge, abnormal digits, 
micrognathia, epicanthic folds, posteriorly rotated ears, microcephaly, bulbous nose and 
high arched palate. Of the 180+ phenotypic features associated with 22qDS, only 18 were 
recorded in the available patient folders.  
I retrospectively examined those features recorded by the attending clinicians (and 
subsequent investigations, e.g. echocardiography) that suggested the correct clinical 
diagnosis of 22qDS. These data were then compared with clinical features and investigations 
that also suggested testing for the microdeletion, but failed to detect 22qDS.  
Other reasons for failure of detection are also discussed, specifically the possibility of false 
negative tests.  
Inclusion criteria included: 
All children at Red Cross Hospital screened for 22qDS with the FISH test were included in 
this study. The age of these children ranged from birth to 18 years of age.  
All patients tested at other referral hospitals and subsequently referred to Red Cross 
Hospital for further management were also included in the study population. These also 
were children that ranged from infancy to 18 years of age. 
Exclusion criteria included: 
Any patients with incomplete or missing folders were excluded from this study. Also, 
patients who had another clear syndromic diagnosis were excluded from the study. 
As classification analysis was being used for the purpose of pattern recognition (and 
therefore not for hypothesis testing), a sample size calculation (power calculation) was not 
required. 
Each patient (in both the experimental arm as well as the control arm) was assigned a study 
number randomly. No names were entered on the electronic database which allowed for 
anonymous analysis and reporting. 
Ethical approval was obtained from the Human Research Ethics committee of the Faculty of 
Health Sciences at the University of Cape Town (reference number HREC/REF; 685/2014). 
Results  
120 FISH positive patients were identified from the NHS Cytogenetics laboratory database. 
However, only 72 of these patients’ folders were located. The missing folders were generally 
of patients who had not been to Red Cross Hospital in the last 10-15 years. These folders 
had been archived and unfortunately have become inaccessible. For this reason, the 
remaining 72 folders were used for this study. A further 72 patients were then randomly 
selected from those who were proven FISH negative from the same cytogenetics laboratory 
database. These 72 FISH negative patients were then used as a control arm for the study. All 
data related to the possible phenotypic features of 22qDS were recorded from the folders. 
The ages of patients ranged from day 1 of life to 18 years of age.  The mean age of 
presentation was 11 months. 
Gender of the enrolled patients was not equally distributed. This had no effect on the study 
as it is well documented in the literature that gender does not affect the prevalence or 
expression of the disease.(1, 4)  
Table 7: Demographics of study  
 FISH positive (n=72) FISH negative (n=72) Total no. patients 
Male  22 44 72 
Female 50 28 72 
Mean age of 
presentation 
12.4 months 8.8 months  
Positive family history 
of 22qDS 
7 6 13 
 
 
   
A positive family history of 22qDS was noted in only 13 of the 144 patients. Of those 13 
patients only 5% (7 out of 144 patients) were proven FISH positive for 22qDS themselves. 
The remainder were FISH negative patients. 
 
It was difficult to ascertain racial demographic data in this study. The race was not always 
noted in the patients’ folders. In some patients, race could be reasonably assumed based on 
the birth name. However, this was not always clear. Particularly, Coloured and White racial 
groups have similar last names in South Africa. In the FISH positive group, 29 patients were 
noted to be Black and 19 patients Coloured. However, the remainder FISH positive patients 
racial group was unknown. For this reason, we could not compare phenotypic features 
accurately between different racial groups. The majority of our patient population was 
clearly non-Caucasian. 
The most common presenting complaints in both groups (FISH positive and FISH negative) of 
patients are listed in table 8. 
Table 8. The main presenting problem in our study population 
PRESENTING PROBLEM No. Patients (%) FISH positive FISH negative 
1. CHD 121 (84%) 64 (44%) 57 (40%) 
- cyanosis  69 (48%) 36 (25%) 33 (23%) 
- CCF 63 (44%) 36 (25%) 27 (19%) 
2. FTT 91 (63%) 48 (33%) 43 (30%) 
3. Dysmorphic features 87 (60%) 46 (32%) 41 (28%) 
4. Developmental delay 70 (49%) 44 (31%) 27 (19%) 
 
Figure 4. Most common presenting features of 22qDS 
 







The majority of patients presented to our centre with a congenital cardiac lesion. This 
included cyanotic and acyanotic cardiac lesions. 44% of the FISH tested patients were 
proven to have 22qDS with a positive FISH test. Other common presenting complaints 
included failure to thrive, dysmorphism, developmental delay, cyanosis and congestive 
cardiac failure. There was minimal missing data with the variables, cyanosis, CHD and 
congestive cardiac failure. This is likely because the majority of patients were transferred to 
our centre with CHD and were closely screened for cardiac signs and symptoms. Some of 
the missing data in the categories FTT and developmental delay were also attributed to the 
fact that some patients presented in the neonatal period, when these parameters are not 
yet detected. Developmental delay occurred commonly as a presenting feature in 22qDS 
FISH positive patients occurring in 30% of patients with 22qDS. Only 19% of FISH negative 
patients were noted to have developmental delay. 
Sensitivity and specificity as well as positive and negative predictive values were calculated 
for all the common presenting complaints. 
30% of patients in this study were acutely ill on admission and required admission to the 
intensive care unit. 19% of these were FISH positive for 22qDS while the remainder were 
FISH negative. 
The positive predictive value (PPV) was highest for congenital heart disease, developmental 
delay and failure to thrive at 88%, 77.1% and 73%, respectively. The negative predictive 
value was highest for cardiac failure (61.9%).  
The presenting complaint with the highest sensitivity for 22qDS was developmental delay, 
with a sensitivity of 62.8%. The specificity of developmental delay was also good at 68%. The 
specificity of congenital heart disease was also good at 65%. The variable of cyanosis was 
not found to be particularly useful, as the sensitivity, specificity and predictive values were 
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Cardiac lesions 
The majority of patients recruited in this study had some sort of cardiac lesion. This may be 
because most patients were referred with cardiac lesions, and cardiologists have a higher 
index of suspicion and are more likely to screen patients for 22qDS. All cardiac lesions were 
congenital and ranged from acyanotic to cyanotic lesions. 121 patients were found to have 
cardiac disease in this study. Of these patients, 44% were proven FISH positive patients with 
22qDS. Current literature reports prevalence of conotruncal CHD between 20-30%, with 
non-conotruncal anomalies occurring in a further 11-20% of patients. Thus, our study 
seemed to reflect the trend of current literature. 5% of our study population had no cardiac 
abnormalities at all, which is somewhat less than the reported percentage in the literature 
(up to 20%). There was no missing data with regards to congenital heart disease. 
Table 10. Prevalence of CHD lesions in study 
Congenital Heart Disease Number (%) of patients affected  
Non-isolated VSD  66 (46%) 
PDA 33 (22.9%) 
Tetralogy of Fallot 30 (20.8%) 
Pulmonary stenosis/ Pulmonary artery stenosis 30 (20.8%) 
ASD 22 (15.2%) 
Truncus arteriosus 21 (14.5%) 
Coarctation of the Aorta 9 (6%) 
Interrupted Aortic arch 9 (6%) 
Transposition of the great arteries 2 (1.4%) 
Aortic stenosis 2 (1.4%) 
Other  27 (18.7%) 
 
Few cardiac defects occurred in isolation. Patients with tetralogy of Fallot were also found 
to have other associated cardiac abnormalities, including a right-sided aortic arch, ASD or 
MAPCA’s. Non-isolated VSD’s were associated with ASD, right-sided aortic arch or 
interrupted aortic arch, PDA, left pulmonary artery stenosis, double outlet right ventricle 
and pulmonary stenosis or PPS. 6 patients also had a truncus arteriosus with VSD present, 
which is to be expected. PDA’s were found in both cyanotic and acyanotic heart lesions, 
namely coarctation of the aorta, VSD, ASD, pulmonary stenosis, transposition of the great 
arteries and univentricular heart. Only 2 patients had TGA and tricuspid atresia. 
Other lesions included AVSD, dilated main pulmonary arteries, MAPCA’s, small pulmonary 
arteries, TAPVD and univentricular heart. 
The sensitivity, specificity, PPV and NPV were calculated for the most common occurring 
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The cardiac variables with the highest sensitivity for 22qDS were truncus arteriosus (71.4%) 
and interrupted aortic arch (77.1%) while the lowest sensitivities were associated with TGA 
and aortic stenosis (which were both 0%). The highest specificity of 22qDS in congenital 
heart disease was non-isolated VSD (57.6%).   
The specificity of truncus arteriosus and interrupted aortic arch were 53.6% and 51.8%, 
respectively. All other cardiac variables ranged in specificity between 47% and 50%. 
The cardiac variable with the highest positive predictive value for 22qDS was non-isolated 
VSD (54.1%). The cardiac variables with the lowest PPV were coarctation of the aorta (1.3%), 
and TGA and aortic stenosis (both 0%). 
Finally, the highest negative predictive value for 22qDS was attributed to TGA (97.2%), 
aortic stenosis (98.6%), interrupted aortic arch (97.2%) and truncus arteriosus (91.6%). 
The cardiac variables with the lowest NPV included PDA (73.6%) and non-isolated VSD 
(62.5%). 
Figure 5. Comparison of the cardiac variables with the highest PPV for 22qDS 
 
Phenotypic features 
The most commonly found phenotypic features of 22qDS in this study are listed in Table 12. 
The most common phenotypic features in this study population included cardiac lesions, 
dysmorphic features, failure to thrive, recurrent infections, developmental delay and 
speech/language abnormalities. The FISH result was more likely to be positive in children 
with cardiac disease, recurrent infections, developmental delay and speech/language 
abnormalities. In the case of failure to thrive and dysmorphic features, FISH positive 












Table 12. Most common phenotypic features recorded in study 
Phenotypic feature FISH positive FISH negative Total Patients 
1. VPI 17 (89%) 2 19 
2. Immune deficiency 14 (87%) 2 16 
3. Thymic aplasia/ hypoplasia 10 (83%) 2 12 
4. Apnoea 6 (75%) 2 8 
5. Hypocalcaemia  28 (73.6%) 10 38 
6. Seizures  17 (73.9%) 6 23 
7. Speech/ language problems 39 (72.2%) 15 54 
8. Cleft palate 9 (69.2%) 4 13 
9. Recurrent infections 55 (63.2%) 32 87 
10. Developmental delay 44 (62.8%) 26 70 
11. Recurrent otitis media 17 (60.7%) 11 28 
12. Feeding problems 29 (60.4%) 19 48 
13. Behavioural issues 9 (60%) 6 15 
14. Stunting 8 (57.1%) 6 14 
15. Dysmorphic features 46 (52.8%) 41 87 
16. Failure to thrive 48 (52.7%) 43 91 
17. Upper airway obstruction 12 (52.1%) 11 23 
18. Cardiac lesion 54 (44.6%) 57 121 
 
Dysmorphic features 
Dysmorphic features were noted in 87 patients in this study. 32% of these patients were 
confirmed FISH positive for 22qDS. Minimal data was missing from the folders (4%). 
35 dysmorphic features noted to occur in association with 22qDS was cross-referenced with 
all 144 patients in our study population. The most commonly occurring dysmorphic features 
are recorded in table 13. 
 





FISH positive FISH negative Total 
Hypertelorism  21 (15%) 16 (10%) 37 
Decreased truncal 
tone 
19 (13%) 15 (10%) 34 
Low set ears 19 (13%) 14(10%) 33 
Abnormal digits 18 (13%) 10 (7%) 28 
Micrognathia  16 (11%) 10 (7%) 26 
Flat nasal bridge 14 (10%) 18 (13%) 32 
Posteriorly rotated 
ears  
15 (10%) 7 (4%) 22 
Epicanthic folds 12 (8%) 13 (8%) 25 
Bulbous nose 9 (6%) 3 (2%) 12 
Microcephaly  7 (5%) 6 (5%) 13 









Figure 3. Dysmorphic features in FISH positive patients versus FISH negative patients for 
22qDS 
 
In general, these common dysmorphic features occurred more in the FISH positive arm of 
the study. Hypertelorism, abnormal digits and posteriorly rotated ears were far more 
common in FISH positive than in FISH negative patients. The only features that occurred in 
equal proportion in both arms (FISH positive and FISH negative patients) were microcephaly, 
abnormal digits, and epicanthic folds. 
The least commonly occurring dysmorphic features included the presence of a third 
fontanel, a thin long face, macrocephaly, low hairline, short sternum and short limbs. Other 
uncommon features in FISH positive patients with 22qDS included large ears, pes planus, 























Table 14. Sensitivity, specificity, positive predictive value and negative predictive value of 
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Figure 4. The PPV of various dysmorphic features in 22qDS 
 
Dysmorphic features with the highest sensitivity for 22qDS were bulbous nose (75%), 
posteriorly rotated ears (68%) and abnormal digits (64%). Posteriorly rotated ears and 
abnormal digits were also associated with the high specificity for 22qDS (53.2% and 53.4%, 
respectively). Other features with similar specificity included hypertelorism (52.3%), bulbous 
nose (52.2%), micrognathia (52.2%) and low set ears (52.2%). 
Lowest sensitivity for the microdeletion syndrome was associated with high arched palate 
(40%), flat nasal bridge (43.7%) and epicanthic folds (48%). 
The highest positive predictive value for 22qDS was with hypertelorism (29.1%), followed by 
truncal hypotonia, low set ears (26.3% each), and abnormal digits (25%). Microcephaly only 
had a PPV of 9.7%. 
The highest negative predictive value for 22qDS was associated with bulbous nose (95.8%), 
high palate (91.6%), microcephaly (91.3%) and posteriorly rotated ears (90.2%). The lowest 
negative predictive values were attributed to truncal hypotonia (79%), hypertelorism (77%) 














This study comprised a folder review of 144 FISH tested patients - 72 patients confirmed 
FISH positive for 22qDS and another 72 patients with features suggestive of 22qDS but FISH 
negative results. The FISH negative patients functioned as the control arm of this study. The 
range of age of presentation of the above-mentioned patients was quite variable (D1 of life 
to 18 years of age). The mean age of presentation was 11 months. 
Even though the FISH database had listed over 120 FISH positive patients with 22qDS over 
the last 20 years, only 72 folders were retrievable. The remaining folders had been archived 
at a separate facility to which we had no access, or the folders had been lost. 
The study population was quite small. For this reason, specific phenotypic features in each 
age group were not done. The neonatal patients were well represented while others were 
poorly represented (namely, the adolescent and older childhood age groups). Thus it was 
decided instead to look at the overall phenotypic features with which children presented at 
our institution. In a follow up study, it would be helpful to attempt a full cluster analysis and 
compare phenotypic features between different age groups. Literature specifically 
pertaining to multi-dimensional analyses in 22qDS is quite scarce. Also, as both genders are 
equally represented in 22qDS, I did not compare findings in males and females. 
In this study, a positive family history of 22qDS was noted in 13 patients (including FISH 
positive and FISH negative patients). Of these 13, only 5% of patients were then proven FISH 
positive for the same syndrome. This was slightly lower than reported in the literature, 
where 7-10% of patients inherit the syndrome from one or both of their parents.(1, 4) This 
may be a falsely low prevalence of disease as the numbers of this study population was 
quite low. Also, family history was not always noted in patients’ folders, so this prevalence 
may be underestimated. 
The main presenting complaints were (in order of decreasing prevalence): CHD, FTT, 
dysmorphic features, developmental delay, cyanosis and congestive cardiac failure. Except 
for cyanosis, all other complaints occurred more commonly in the FISH positive group as 
compared to the FISH negative group. 44% of all the patients with CHD in this study were 
noted to be FISH positive. However, in FISH positive patients, the prevalence of CHD was 
88%. The prevalence of CHD in our study is noted to be higher than other studies, including 
Oskarsdottir et al, where 54% of FISH positive patients had CHD (many which occurred in 
the younger age group) and McDonald-McGinn et al, whose research at CHOP yielded a 
prevalence of 77% for CHD in 22qDS.(5, 10) Studies in non-Caucasian populations also 
yielded lower rates of CHD of 50-60%.(38, 41) The high prevalence of CHD in our population 
may be attributed to bias as most our patients were recruited from the cardiology 
department at RCWMCH. Our hospital is a major referral hospital for children in Sub 
Saharan Africa.  
The majority of patients were referred to our centre for further management of their 
cardiac issues. The high prevalence of cardiac disease in FISH positive patients in this study 
may also be due to increased screening of cardiac defects in patients known with 22qDS. 
Other presenting complaints, like developmental delay or failure to thrive were less likely to 
be referred to our institution as they can be managed effectively at their presenting 
hospitals. 
The prevalence of FTT in FISH positive patients was 66%, while the prevalence of 
developmental delay in FISH positive patients was 61%.  63% of FISH positive patients 
presented with dysmorphic features. However, this data may be somewhat skewed as some 
of the data pertaining to these features were missing from some folders.  
66% of patients presented with failure to thrive. This phenotypic feature is not described 
well in the literature. It may well be that the high prevalence of failure to thrive be due to 
the poor social circumstances of this patient population and the suboptimal economic 
climate of our country, South Africa being a low to middle income country.  
Developmental delay was noted in 61% of FISH positive patients in this current study. This 
was lower than described by Oskarsdottir et al where developmental delay occurred in 96% 
of their study population. 20% of these cases involved behavioural issues.(10) 
Veerapandiyan et al found that, in the African- American population, developmental delay 
occurred in 58% of patients with 22qDS.(38) Repetto et al, in a Chilean study on 22qDS, 
noted developmental delay in 85% of patients with the syndrome.(41) Our study yielded a 
lower prevalence of developmental delay than that of the current literature, with the 
exception of the study done by Veerapandiyan et al. This may be due to population bias, 
with our neonatal study population numbers being greater than the older 
childhood/adolescent population numbers. 
Palatal involvement and feeding abnormalities were not as common a presenting feature in 
this study as compared to other studies. Recurrent infections were common in this study, 
but it was uncertain if this was due to an underlying immune deficiency or due to possible 
invasive procedures performed at our centre i.e. cardiac catheterization, post-operative 
complication of cardiac surgery, recurrent aspiration secondary to VPI or truncal hypotonia 
and severe malnutrition. Prevalence of immune deficiency and thymic abnormalities was 
not evaluated as most patients had this data missing from their folders. This is likely because 
many clinicians find these issues to be of less diagnostic value for 22qDS and are more likely 
to screen patients for these problems once the diagnosis has been confirmed, and patients 
present with signs or symptoms suggestive of these disorders. 
 
 
Because this was a descriptive study, the aim was to focus on the phenotypic features of 
22qDS which would be most helpful in the clinical screening of the syndrome. The 
presenting complaint with the highest sensitivity and specificity for 22qDS was 
developmental delay (62.8% and 68%, respectively). The specificity of CHD for 22qDS was 
also good as at 65%. Positive predictive value was highest for CHD and FTT at 88% and 73%, 
respectively. The negative predictive value was highest for cardiac failure. The variable of 
cyanosis was not found to be particularly useful, as the sensitivity, specificity and predictive 
values were all just above 50%. 
121 out of 144 patients were found to have cardiac disease. Of these patients, 44% were 
proven FISH positive patients with 22qDS. Current literature reports prevalence of 
conotruncal CHD between 20-30%, with non-conotruncal anomalies occurring in a further 
11-20% of patients. Thus, our study seemed to reflect the trend of current literature. 5% of 
the study population had no cardiac abnormalities at all, which is somewhat less than the 
reported percentage in the literature (up to 20%). 
The most common cardiac lesions associated with FISH positive patients in this study 
included: non-isolated VSD (27%), tetralogy of Fallot (11%), truncus arteriosus (10%), 
PS/pulmonary artery stenosis (8%), ASD (7%) and interrupted aortic arch (5%). No AS, TGA 
or TAPVD was noted in any FISH positive patients in this study. The current study compared 
to previous studies as follows: the most common cardiac lesion described in patients with 
22qDS was VSD (27%). This was similar to the prevalence quoted by McDonald-McGinn 
(21%).(1) Prevalence of TOF (11%) was described in this study as comparable to the 
prevalence of 13% by Peyvandi et al.(42) However, studies done by both McDonald McGinn 
and Repetto et al had a slightly higher prevalence of TOF in their study population (both 
were 20%).(1, 41) In this study, truncus arteriosus was described in 10% of patients with 
22qDS. This is much lower than described in Peyvandi et al (35%).(42) However, it is only 
slightly higher than described in McDonald-McGinn and Repetto et al.(1, 41) IAA was 
reported far less than was reported in studies by McDonald- McGinn and Peyvandi et al, but 
had a similar prevalence to the study done by Repetto et al.(1, 41, 42) 
Few cardiac lesions occurred in isolation in patients with 22qDS. Cardiac lesions associated 
with right sided aortic arch, DORV, MAPCA’s were more likely to be FISH positive patients. 
This is in agreement with the current literature. 
In this study, the cardiac lesion with the highest sensitivity for 22qDS was truncus arteriosus 
(71.4%). IAA was also associated with a high sensitivity for 22qDS (77.7%). The least 
sensitive cardiac lesion was noted to be PS/Pulmonary artery stenosis (40%). The cardiac 
lesions with the highest specificity for 22qDS were VSD and TA (57.6% and 53.6%, 
respectively). 
The cardiac lesion with the highest positive predictive value for 22qDS was non-isolated VSD 
(54%), while the lowest PPV was attributed to TGA and AS (both 0%). The lesions with the 
highest NPV included AS (98.6%), TGA (97.2%) and IAA (97.2%). 
More than 180 phenotypic features are associated with 22qDS.(6) Not all of this data was 
available from patients’ folders as many folders were already archived at a remote facility, 
incomplete or missing. 
Oskarsdottir et al found that 35% of children less than 2 years of age and 53% of children 
older than 2 years of age with 22qDS were noted to be dysmorphic.(10) McDonald-McGinn 
et al described dysmorphic features as important minor phenotypic features of the 
syndrome. These included bulbous nose, hooded eyelids and micrognathia (60%, 25% and 
21%, respectively).(1, 5) Another multi-centre study done by Veerapandiyan et al on African-
American patients with 22qDS showed 64% of patients presented with ear abnormalities, 
including low set ears, posteriorly rotated ears and abnormal helices of the ears. 40% of 
patients had a wide nasal bridge. 22% of patients had short palpebral fissure. Less 
commonly described were patients with micrognathia (16%), hypertelorism (14%), bulbous 
nose (12%) and hooded eyelids (12%).(38) Finally, Oskarsdottir et al in another study in 
2008, described the facial features of 90 children with 22qDS. More than 50%of patients 
presented with malar flatness, hooded eyelids, bulbous nose, round or broad ears, thick or 
overfolded helices of the ear and low set ears.(39) 
In this study at Red Cross War Memorial Children’s Hospital, 87 of the 144 patients in our 
study were noted to be dysmorphic. Of these, 32% were confirmed 22qDS with positive FISH 
test. Considering the majority of our study population were younger children and infants, 
this number is in keeping with the current literature. The most common dysmorphism 
features in patients with 22qDS were noted to be hypertelorism (15%), truncal hypotonia 
(13%), low set ears (13%), abnormal digits (13%), micrognathia (11%) and posteriorly 
rotated ears (10%). The presence of a bulbous nose was only noted to be present in 6% of 
the patients with 22qDS. (62) These figures correlated more with the study by 
Veerapandiyan, in the African American population with 22qDS, though ear abnormalities 
occurred far less than described in the aforementioned study. This may be because the 
majority of our study population is also non-Caucasian.(38) 
The dysmorphic features with the highest sensitivity for 22qDS were bulbous nose (75%) 
and posteriorly rotated ears (68%), while the high arched palate had the lowest sensitivity at 
40%. The highest specificity was noted to be abnormal digits and posteriorly rotated ears 
(53% for both). Again, the lowest specificity was associated with high arched palate and 
microcephaly (both 49%). The highest PPV for 22qDS was associated with hypertelorism 
(29%) and truncal hypotonia (26%).  
Lastly the highest NPV was associated with bulbous nose (95.8%), high arched palate 
(91.6%) and microcephaly (91.3%). The features with the lowest NPV included a flat nasal 
bridge (75%) and hypertelorism (77.7%). 
Current guidelines for the screening of 22qDS include the Oskarsdottir score (See table 
below).(10) However, at present, this guideline has been largely ineffective in our particular 
population at RCWMCH. This is likely due to the fact that the above mentioned study was 
performed in Sweden and consisted of a largely Caucasian population group. It is well 
documented that non-Caucasian population groups often have different phenotypic 
features. Our current review on the phenotypic features of children with 22qDS has 
revealed the most common presentations to be CHD, FTT, dysmorphic features as described 
above, and cardiac failure. Younger children present more frequently with CHD, while older 
children present with developmental delay and dysmorphic features. Our particular 22qDS 
patient population presented with the following CHD: non-isolated VSD, tetralogy of Fallot, 
truncus arteriosus, PS/pulmonary artery stenosis and interrupted aortic arch. Interrupted 
aortic arch was found to be a sensitive marker for 22qDS in children with cardiac lesions. 
Table 15. Guidelines for testing for 22qDS (10) 
CLINICAL DOMAIN INFANTS PRESCHOOL 
CHILDHOOD TO 
ADOLESCENCE 
1. Cardiac defect Cardiac defect (TOF, 
IAA, truncus arteriosus, 
PA+VSD, VSD+arch 
anomaly) 
   




















3. Abnormal calcium 
metabolism 
Hypocalcaemia  Hypoparathyroidism  Hypoparathyroidism  
4. Poor feeding Poor feeding Poor feeding Poor feeding 
















   
Other abnormalities 
(skeletal, clubfoot, 




hernia, etc), including 
scoliosis  
  
8. Dysmorphic features Dysmorphic features Dysmorphic features Dysmorphic features 
2 or more of the following 8 clinical domains are required to consider the use of genetic testing for 
possible 22qDS; If a typical cardiac defect is found in infancy, this is sufficient for testing for 22qDS. 
Other important phenotypic features shown to be less prevalent in our population included 
primary immune deficiency, thymus abnormalities, cleft palate, velo-pharyngeal 
insufficiency, feeding abnormalities and behavioural issues. It is not certain whether this is a 
true reflection of our population’s features as there was missing data in a large portion of 
folders regarding these particular features. 
 This study has several strengths: The phenotypic features of 22qDS in our local population 
were described for the first time. This study also had a control arm of FISH negative 
patients, and thus comparative analysis could be done to ascertain the features that best 
predicted a clinical diagnosis of 22qDS. A further study on the phenotypic features of 22qDS 
using multi dimensional analysis in this same population group will aid clinical recognition of 
the syndrome. There are very few studies published on multi dimensional analysis to date.  
However, there were also several limitations to this study. The study population was small 
and there were several folders that were archived and unobtainable for review. Also, many 
folders were incomplete with variable amounts of missing data. This is likely because many 
folders were from specialist clinics and thus focussed on particular complications of 22qDS 
as opposed to thorough assessment of all the features of the syndrome. Another limitation 
was the inability to describe the demographics of our study population accurately. Many 
patient folders did not specify the race of the patient. While most patients were clearly non- 
Caucasian by way of their birth names, it was particularly difficult to separate Caucasian 
patients from Coloured patients as their names were often very similar. Lastly, DORV was 
intermittently recorded in patients’ folders as occurring in the presence of a VSD. This does 
not occur pathophysiologically however. Thus the data for VSD positive patients with 22qDS 
may not be completely accurate and may in fact, have a slightly lower prevalence in 22qDS. 
In conclusion, it is clear that non-Caucasian populations have some unique phenotypic 
expressions of 22qDS. It is imperative that clinicians maintain a high index f suspicion for 
patients with 22qDS. All children with conotruncal abnormalities should be screened for 
22qDS. Also, all children with CHD as well as IAA should also be screened for 22qDS as this 
has been shown to be a sensitive marker for this syndrome. Patients presenting with CHD, 
FTT, dysmorphic features and developmental delay should also be screened for 22qDS as 
these have been shown to be the most common phenotypic expression of disease in our 
geographical context. 
There are very few studies on multidimensional analysis of 22qDS, particularly in non-
Caucasian population groups. It would be helpful in a follow up study to further describe the 
phenotypic features of this syndrome, specifically looking at clusters of features that may 
occur within our population that may prove to be more sensitive for 22qDS. We also hope 
to do a complete cluster analysis on these same features and finally, to develop an 
algorithm to better identify patients with 22qDS in our setting. A future study should 
ascertain which cluster of phenotypic features are most common in each particular age 
group. 
This could be done using classification trees to analyse each individual variable, and in this 
way establishing whether certain features cluster together in 22qDS patients in our setting. 
This can then be converted to a possible scoring system which could be tested in a 























Bassett el al (20) suggested some practical guidelines in the management of patients with 
22qDS. Different screening tests are suggested at various ages. 
In 2011, Bassett et al published guidelines on the management of 22qDS.  The guidelines 
were based on two international 22qDS consensus meetings, as well as a systematic review 
of 239 publications on 22qDS. Guidelines published included a list of the multi system 
features, recommendations at diagnosis and considerations for genetic counselling.(13) 
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